1 citations · 1 across the 4 of their papers we have counts for
4 papers
Active-Controlled Trial Design for HIV Prevention Trials with a Counterfactual Placebo
Fei Gao, Holly Janes, Susan Buchbinder +1
In the quest for enhanced HIV prevention methods, the advent of antiretroviral drugs as pre-exposure prophylaxis (PrEP) has marked a significant stride forward. However, the ethica…
Addressing Population Heterogeneity for HIV Incidence Estimation Based on Recency Test
Qi Wang, Ann Duerr, Fei Gao
Cross-sectional HIV incidence estimation leverages recency test results to determine the HIV incidence of a population of interest, where recency test uses biomarker profiles to in…
An Enhanced Cross-Sectional HIV Incidence Estimator that Incorporates Prior HIV Test Results
Marlena Bannick, Deborah Donnell, Richard Hayes +2
Incidence estimation of HIV infection can be performed using recent infection testing algorithm (RITA) results from a cross-sectional sample. This allows practitioners to understan…
Generalizing the intention-to-treat effect of an active control against placebo from historical placebo-controlled trials to an active-controlled trial: A case study of the efficacy of daily oral TDF/FTC in the HPTN 084 study
Qijia He, Fei Gao, Oliver Dukes +2
In many clinical settings, an active-controlled trial design (e.g., a non-inferiority or superiority design) is often used to compare an experimental medicine to an active control…